RxDoctor Payments Data

Jeffrey Dysart, MD

Family Medicine · San Diego, CANPI 1154361558

Payments from drug & device makers

$16,504in general payments, 2019–2025

Across 726 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$2K
  • GSK$1K
  • Amgen$1K
  • Novo Nordisk$912
  • Lilly USA, LLC$715
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$2,50015%
  • Food & beverage$14,00485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,504 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$64,492
Medicare patients
176
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$50,095
OzempicSemaglutide37$39,982
EliquisApixaban39$29,076
FarxigaDapagliflozin Propanediol25$28,527
XareltoRivaroxaban12$18,127
MounjaroTirzepatide11$10,955
MyrbetriqMirabegron13$10,953
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,218
Spiriva RespimatTiotropium Bromide15$7,748
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,709
Atorvastatin Calcium182$2,052
Omeprazole96$1,812
Rosuvastatin Calcium69$1,662
Lisinopril150$1,400
Diclofenac Sodium14$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$189$57,84362 claims
Novo NordiskOzempic$912$39,98237 claims
PfizerEliquis$572$29,07639 claims
AstraZenecaFarxiga$1,801$28,52725 claims
Johnson & JohnsonXarelto$170$18,12712 claims
Lilly USA, LLCMounjaro$715$10,95511 claims
Astellas Pharma US IncMyrbetriq$208$10,95313 claims
GSKTrelegy Ellipta$1,246$8,21811 claims
AbbVieSynthroid$4,293$99312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →